Cargando…

The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States

Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Horn, Elizabeth J., Dempsey, George, Schotthoefer, Anna M., Prisco, U. Lena, McArdle, Matthew, Gervasi, Stephanie S., Golightly, Marc, De Luca, Cathy, Evans, Mel, Pritt, Bobbi S., Theel, Elitza S., Iyer, Radha, Liveris, Dionysios, Wang, Guiqing, Goldstein, Don, Schwartz, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269379/
https://www.ncbi.nlm.nih.gov/pubmed/32102853
http://dx.doi.org/10.1128/JCM.00032-20
_version_ 1783541764110417920
author Horn, Elizabeth J.
Dempsey, George
Schotthoefer, Anna M.
Prisco, U. Lena
McArdle, Matthew
Gervasi, Stephanie S.
Golightly, Marc
De Luca, Cathy
Evans, Mel
Pritt, Bobbi S.
Theel, Elitza S.
Iyer, Radha
Liveris, Dionysios
Wang, Guiqing
Goldstein, Don
Schwartz, Ira
author_facet Horn, Elizabeth J.
Dempsey, George
Schotthoefer, Anna M.
Prisco, U. Lena
McArdle, Matthew
Gervasi, Stephanie S.
Golightly, Marc
De Luca, Cathy
Evans, Mel
Pritt, Bobbi S.
Theel, Elitza S.
Iyer, Radha
Liveris, Dionysios
Wang, Guiqing
Goldstein, Don
Schwartz, Ira
author_sort Horn, Elizabeth J.
collection PubMed
description Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository. Testing was performed to confirm the presence of tick-borne pathogens by real-time PCR, and a subset of samples was tested for Borrelia burgdorferi by culture. Serology was performed on all samples using the CDC’s standard two-tiered testing algorithm (STTTA) for LD. LD diagnosis was supported by laboratory testing in 82 cases, including positive results by use of the STTTA, PCR, or culture or positive results by two enzyme-linked immunosorbent assays for cases presenting with EM lesion sizes of >5 cm. The remaining 216 cases had negative laboratory testing results. For the controls, 43 were positive by at least one of the tiers and 6 were positive by use of the STTTA. The results obtained with this collection highlight and reinforce the known limitations of serologic testing in early LD, with only 29% of individuals presenting with EM lesion sizes of >5 cm yielding a positive result using the STTTA. Aliquots of whole blood, serum, and urine from clinically characterized patients with and without LD are available to investigators in academia and industry for evaluation or development of novel diagnostic assays for LD, to continue to improve upon currently available methods.
format Online
Article
Text
id pubmed-7269379
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-72693792020-06-09 The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States Horn, Elizabeth J. Dempsey, George Schotthoefer, Anna M. Prisco, U. Lena McArdle, Matthew Gervasi, Stephanie S. Golightly, Marc De Luca, Cathy Evans, Mel Pritt, Bobbi S. Theel, Elitza S. Iyer, Radha Liveris, Dionysios Wang, Guiqing Goldstein, Don Schwartz, Ira J Clin Microbiol Immunoassays Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository. Testing was performed to confirm the presence of tick-borne pathogens by real-time PCR, and a subset of samples was tested for Borrelia burgdorferi by culture. Serology was performed on all samples using the CDC’s standard two-tiered testing algorithm (STTTA) for LD. LD diagnosis was supported by laboratory testing in 82 cases, including positive results by use of the STTTA, PCR, or culture or positive results by two enzyme-linked immunosorbent assays for cases presenting with EM lesion sizes of >5 cm. The remaining 216 cases had negative laboratory testing results. For the controls, 43 were positive by at least one of the tiers and 6 were positive by use of the STTTA. The results obtained with this collection highlight and reinforce the known limitations of serologic testing in early LD, with only 29% of individuals presenting with EM lesion sizes of >5 cm yielding a positive result using the STTTA. Aliquots of whole blood, serum, and urine from clinically characterized patients with and without LD are available to investigators in academia and industry for evaluation or development of novel diagnostic assays for LD, to continue to improve upon currently available methods. American Society for Microbiology 2020-05-26 /pmc/articles/PMC7269379/ /pubmed/32102853 http://dx.doi.org/10.1128/JCM.00032-20 Text en Copyright © 2020 Horn et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Immunoassays
Horn, Elizabeth J.
Dempsey, George
Schotthoefer, Anna M.
Prisco, U. Lena
McArdle, Matthew
Gervasi, Stephanie S.
Golightly, Marc
De Luca, Cathy
Evans, Mel
Pritt, Bobbi S.
Theel, Elitza S.
Iyer, Radha
Liveris, Dionysios
Wang, Guiqing
Goldstein, Don
Schwartz, Ira
The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title_full The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title_fullStr The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title_full_unstemmed The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title_short The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
title_sort lyme disease biobank: characterization of 550 patient and control samples from the east coast and upper midwest of the united states
topic Immunoassays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269379/
https://www.ncbi.nlm.nih.gov/pubmed/32102853
http://dx.doi.org/10.1128/JCM.00032-20
work_keys_str_mv AT hornelizabethj thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT dempseygeorge thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT schotthoeferannam thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT priscoulena thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT mcardlematthew thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT gervasistephanies thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT golightlymarc thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT delucacathy thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT evansmel thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT prittbobbis thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT theelelitzas thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT iyerradha thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT liverisdionysios thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT wangguiqing thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT goldsteindon thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT schwartzira thelymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT hornelizabethj lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT dempseygeorge lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT schotthoeferannam lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT priscoulena lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT mcardlematthew lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT gervasistephanies lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT golightlymarc lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT delucacathy lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT evansmel lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT prittbobbis lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT theelelitzas lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT iyerradha lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT liverisdionysios lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT wangguiqing lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT goldsteindon lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates
AT schwartzira lymediseasebiobankcharacterizationof550patientandcontrolsamplesfromtheeastcoastanduppermidwestoftheunitedstates